Abstract

This project is designed to prepare a GMP quality investigational HIV vaccine and complete the preclinical and laboratory studies needed for clinical studies of a multicomponent HIV-1 adenoviral vector vaccine. The hypothesis is that the vaccine will be safe for human administration and elicit immune responses to HIV-1. Subjects receive adenovector vaccine either as a single agent or as a boost after priming with plasmid DNA vaccines.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI005041-05
Application #
7299842
Study Section
(VPP)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2006
Total Cost
Indirect Cost

  Institution

Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Cheng, Cheng; Gall, Jason G D; Kong, Wing-pui et al. (2007) Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 3:e25
Sheets, R L (2006) Adventitious agent test methods. Dev Biol (Basel) 123:135-45; discussion 183-97
Sheets, Rebecca (2006) Assaying potency of novel vaccines. October 11-12, 2005, Bethesda, MD, USA. Expert Rev Vaccines 5:315-8
Butman, B T; Lizonova, A; Brough, D E et al. (2006) Comprehensive characterization of the 293-ORF6 cell line. Dev Biol (Basel) 123:225-33; discussion 265-6